Table 1.
Description of the samples used in the present study
| Bonn1CSF | Bonn2CSF | ADNI | ADC | AD dementia patients |
Healthy controls |
|||
|---|---|---|---|---|---|---|---|---|
| Bonn1 : 438 | Bonn2 : 641 | Bonn1 : 1179 | Bonn2 : 1096 | |||||
| N | 113 | 167 | 83 | 515 | 1079 | 2275 | ||
| Age (years ± SD) | 71.6 (±7.4) | 71.8 (±7.7) | 74.8 (±7.5) | 66.4 (±8.8) | 73.3 (±8.8) | 56.7 (±13.8) | ||
| F : M ratio | 1.26 | 1.19 | 1 | 1.05 | 1.7 | 1.3 | ||
| Aβ1–42 (±SD) | 478.3 (±186.5) | 529.2 (±238.1) | 149.4 (±51.1) | 462.5 (±147.9) | NA | NA | NA | NA |
| pTau181 (±SD) | 87.5 (±36.5) | 88.6 (±45.2) | 39.5 (±20.1) | 88.2 (±38.8) | NA | NA | NA | NA |
| Genotype platform | Illumina 610 | Illumina 1M-quad | Illumina 610 | Sequenom | Bonn1 : 438 | Bonn2 : 641 | Bonn1 : 1179 | Bonn2 : 1096 |
| Illumina 610 | Illumina 1M-quad | Illumina HumanHap550k | Illumina 1M-quad | |||||
F : M ratio, female : male ratio; SD, standard deviation. Aβ1–42, amyloid-beta 1–42; pTau181, phosphorylated Tau at position 181; AD, Alzheimer's disease; CSF, cerebrospinal fluid; ADNI, Alzheimer's Disease Neuroimaging Initiative cohort; ADC, Amsterdam Dementia Cohort.